文献速递造血干细胞移植与细胞治疗淋巴瘤

髓系来源抑制细胞抑制移植物抗宿主病同时保留移植物抗白血病效应的机制研究

The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
PubMed 文献 · Leukemia · 2019-02-08

本研究在多种小鼠移植物抗宿主病(GVHD)与移植物抗白血病(GVL)模型中,探讨CD115+髓系来源抑制细胞(MDSC)能否控制GVHD而不损害GVL。结果显示CD115+ MDSC治疗有效抑制GVHD而不显著损害GVL活性,并鉴定出供者来源NKG2D+ CD8记忆表型T细胞的出现是这一分离效应的机制。

要点

  • CD115+ MDSC治疗在小鼠GVHD和GVL模型中分别提供80%和67%的保护。
  • MDSC治疗有效抑制GVHD但不显著损害GVL活性。
  • 供者T细胞NKG2D表达是清除同种异体淋巴瘤细胞所必需的。

核心结论

  • MDSC可作为新型细胞疗法,通过选择性诱导NKG2D+ CD8记忆T细胞来抑制GVHD同时维持GVL活性。

研究设计与样本

  • 使用多种小鼠GVHD/GVL模型,包括MHC错配和miHA错配模型,研究CD115+ MDSC治疗对GVHD和GVL的影响。

主要发现

  • CD115+ MDSC治疗在GVHD和GVL模型中分别使治疗小鼠获得80%和67%的保护。
  • MDSC治疗有效抑制GVHD但不显著损害GVL活性。
  • MDSC治疗受者小鼠中出现供者来源的NKG2D+ CD8记忆表型T细胞。
  • 供者T细胞上的NKG2D表达是清除同种异体淋巴瘤细胞所必需的。
  • 长期存活的MDSC受者小鼠对同种异体白血病细胞具有细胞溶解活性,且调节性T细胞和NKG2D+ CD8 T细胞百分比显著增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is a major barrier to the widespread use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treating hematologic malignancies. Myeloid-derived suppressor cells (MDSCs) have been recognized as crucial immunosuppressive cells in various pathologic settings. Here, we investigated whether the unique functional properties of MDSCs could be harnessed to control allo-HSCT-associated GVHD. Using multiple murine GVHD/GVL models including both MHC-mismatched and miHA-mismatched, we demonstrated that treatment with CD115+ MDSCs efficiently suppressed GVHD but did not significantly impair graft-versus-leukemia (GVL) activity, leading to 80 and 67% protection in treated mice in GVHD and GVL models, respectively. The mechanism for this dissociation of GVHD from GVL, specifically the emergence of donor-derived NKG2D+ CD8 T cells with a memory phenotype in MDSC-treated recipient mice, was identified. NKG2D expression on donor T cells was required for eradication of allogeneic lymphoma cells. Furthermore, long-term surviving MDSC recipients that exhibited cytolytic activities against allogeneic leukemia cells had a significantly increased percentage of T regulatory cells and, more importantly, NKG2D+ CD8 T cells. These findings indicate that MDSCs can be used as a novel cell-based therapy to suppress GVHD while maintaining GVL activities through selective induction of NKG2D+ CD8 memory T cells.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang J, Chen HM, Ma G, et al. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells. Leukemia. 2019. PMID: 30737483. doi:10.1038/s41375-019-0394-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。